Integrated Biopharma Inc (INBP): Operating Cash Flow
$1.24M
Year ended 2026-06-30
+0.2%
3-year compound annual growth
-16.5%
5-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $1.24M | -39.9% | 2026-09-25, From 2025-07-01 |
| 2025-06-30 | $2.06M | +119.0% | 2026-09-25, From 2024-07-01 |
| 2024-06-30 | $943.0K | -23.5% | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $1.23M | -69.9% | 2024-09-20, From 2022-07-01 |
| 2022-06-30 | $4.09M | +34.1% | 2023-09-15, From 2021-07-01 |
| 2021-06-30 | $3.05M | +127.8% | 2022-09-13, From 2020-07-01 |
| 2020-06-30 | $1.34M | +308.2% | 2021-09-02, From 2019-07-01 |
| 2019-06-30 | $328.0K | -71.9% | 2020-09-23, From 2018-07-01 |
| 2018-06-30 | $1.17M | +194.2% | 2019-08-29, From 2017-07-01 |
| 2017-06-30 | $397.0K | n/m | 2018-09-12, From 2016-07-01 |
| 2016-06-30 | -$594.0K | n/m | 2017-09-01, From 2015-07-01 |
| 2015-06-30 | -$113.0K | n/m | 2015-09-04, From 2014-07-01 |
| 2014-06-30 | $1.88M | n/m | 2015-09-04, From 2013-07-01 |
| 2013-06-30 | -$1.44M | n/m | 2014-09-08, From 2012-07-01 |
| 2012-06-30 | -$771.0K | n/m | 2013-09-30, From 2011-07-01 |
| 2011-06-30 | $392.0K | n/a | 2012-10-15, From 2010-07-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $1.24M | -39.9% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$4.99M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.93M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$52.43M | n/m |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | -$187.49M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | $110.19M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $57.67M | -68.7% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | -$13.36M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$171.27M | n/m |
Compare INBP, XLO, CPIX, AQST side by side · Screen every company in Pharmaceutical Preparations ↗